The retrospective study aimed to test the efficacy and tolerability of Atezolizumab + Bevacizumab in pts with HCC. The combination Atezolizumab + Bevacizumab was well-tolerable and effective in HCC. One of the most common causes of cancer-related death worldwide is hepatocellular carcinoma (HCC). Atezolizumab combined with Bevacizumab ( Atezolizumab + Bevacizumab) has been […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Melanoma, the most lethal form of skin cancer, has undergone a transformative treatment shift with the advent of checkpoint blockade immunotherapy (CBI). Understanding the intricate network of immune cells infiltrating the tumor and orchestrating the …
Background Immune-related hepatitis (irHepatitis) is a relatively common immune-related adverse event (irAE) of checkpoint inhibitors. Often, it responds well to steroids; however, in refractory cases, further therapy is needed. Anti-tumor necrosis factor (TNF) antibodies are used …
Objectives: Disparities exist in the length and quality of survival from melanoma. This study evaluated, in a Texas cohort, patient factors associated with melanoma survival and examined if newer immune-oncologic agents extend survival compared with …
